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Background: TNM staging alone does not accurately predict outcome in colon cancer (CC) patients who may be eligible for
adjuvant chemotherapy. It is unknown to what extent the molecular markers microsatellite instability (MSI) and mutations in
BRAF or KRAS improve prognostic estimation in multivariable models that include detailed clinicopathological annotation.
Patients and methods: After imputation of missing at random data, a subset of patients accrued in phase 3 trials with
adjuvant chemotherapy (n¼ 3016)—N0147 (NCT00079274) and PETACC3 (NCT00026273)—was aggregated to construct
multivariable Cox models for 5-year overall survival that were subsequently validated internally in the remaining clinical trial
samples (n¼ 1499), and also externally in different population cohorts of chemotherapy-treated (n¼ 949) or -untreated
(n¼ 1080) CC patients, and an additional series without treatment annotation (n¼ 782).
Results: TNM staging, MSI and BRAFV600E mutation status remained independent prognostic factors in multivariable models
across clinical trials cohorts and observational studies. Concordance indices increased from 0.61–0.68 in the TNM alone model
to 0.63–0.71 in models with added molecular markers, 0.65–0.73 with clinicopathological features and 0.66–0.74 with all
covariates. In validation cohorts with complete annotation, the integrated time-dependent AUC rose from 0.64 for the TNM
alone model to 0.67 for models that included clinicopathological features, with or without molecular markers. In patient co-
horts that received adjuvant chemotherapy, the relative proportion of variance explained (R2) by TNM, clinicopathological fea-
tures and molecular markers was on an average 65%, 25% and 10%, respectively.
Conclusions: Incorporation of MSI, BRAFV600E and KRAS mutation status to overall survival models with TNM staging improves
the ability to precisely prognosticate in stage II and III CC patients, but only modestly increases prediction accuracy in
multivariable models that include clinicopathological features, particularly in chemotherapy-treated patients.
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Introduction
Colon cancer (CC) is a leading cause of cancer mortality world-
wide [1, 2]. Initial patient management is defined by TNM stage
at diagnosis, based on depth of tumor wall invasion, lymph node
involvement and distant metastasis. This simple staging system,
now at its seventh edition, is widely used, clinically useful and is
highly associated with 5-year overall survival (OS), ranging from
92% in stage I to 11% in stage IV [3]. However, in patients with
stage II and III CC, TNM staging less clearly distinguishes groups
of patients with different prognosis, particularly in those who re-
ceive adjuvant chemotherapy, with 5-year OS between 50% and
90% [3]. Additional patient or disease characteristics known to
affect survival in CC, including age, sex, primary site location,
tumor grade, number of positive lymph nodes (LNs), number of
examined LNs, lymphovascular and perineural invasion, bowel
obstruction or perforation, and adjuvant treatment (fluoropyri-
midine single agent or in combination with oxaliplatin) [4–6],
are currently not directly included in American Joint
Commission on Cancer (AJCC)-based risk determinations.
The AJCC has increasingly recognized the growing need for
more accurate and probabilistically based outcome prediction for
precision medicine by incorporating additional anatomic and
nonanatomic prognostic factors. This could be achieved through
the use of accurate risk models and web-based calculators. The
AJCC Precision Medicine Core has recently established inclusion
and exclusion criteria necessary for a risk model to potentially be
endorsed by the AJCC, with the emphasis centered on perform-
ance metrics, implementation clarity, and clinical relevance [7].
Recommended performance measures in survival analysis in-
clude concordance index (c-index) and time-dependent area
under the curve (tAUC). The c-index represents the probability
that a model will correctly predict which of two randomly se-
lected patients will experience an event before the other. The
tAUC involves computing sensitivity and specificity at multiple
time points, which provides more comprehensive information
about the model predictive power than the c-index. The inte-
grated (iAUC) is a weighted time-averaged summary of tAUC.
Previously, to estimate the value of clinicopathological covari-
ates in prognosis prediction in stage III CC, data from close to
16 000 patients accrued to phase III clinical trials were aggregated
(ACCENT database) and used to construct multivariable Cox
models for OS [4]. Authors have shown that both patient and dis-
ease characteristics provide clinically significant information for
OS prediction and developed calculators that better discriminate
patient risk than does TNM staging alone [8]. Of note, the c-
index rose from 0.58 for the TNM system model to 0.66 for the
model that included TNM and detailed clinicopathological anno-
tation [4]. These numbers confirm that there is room for im-
provement of prognosis prediction in intermediate-risk CC.
Indeed, biomarker analysis of multiple studies strongly supports
the feasibility of refining risk stratification by factoring in mo-
lecular characteristics with tumor staging [9]. In stage II disease,
e.g. microsatellite instability (MSI) defines a population with low
recurrence rates and very good outcome without adjuvant treat-
ment [10, 11]. BRAFV600E or KRAS mutations confer worse sur-
vival in patients with stage II and III disease, and their value as
additional risk factors is greater when MSI status and primary
tumor location are taken into account [12–14].
In this article, we assess whether the addition of cancer cell mo-
lecular markers (MSI, BRAFV600E mutations and KRAS muta-
tions) can improve prediction of OS over traditional
clinicopathological covariates in patients with nonmetastatic CC.
To meet the high levels of evidence required by the AJCC for po-
tential endorsement, the project involved multiple institutions
capable of contributing expertise and large cohorts, both clinical
trial data and observational studies. Here we present the results of
this effort, first with a description of how molecular markers of
interest associate with selected clinicopathological features, then
with a detailed performance analysis of models containing TNM
staging, clinicopathological and/or molecular markers in mul-
tiple validation cohorts.
Methods—patients
Our study population included 8904 patients diagnosed with stage I–III
CC, treated or untreated with adjuvant chemotherapy, with clinicopatho-
logical and molecular annotation for variables of interest. Patients diag-
nosed with rectal cancer or stage IV CC were not eligible, and those with
stage I CC (n¼ 832) were included only in the descriptive correlative ana-
lysis and excluded from survival models (Figure 1). The endpoint of inter-
est was 5-year OS, measured from time of cancer diagnosis until death
from any cause, censored at last follow-up or at 5-year post-diagnosis. The
covariates considered for inclusion in the models were as follows:
1. TNM stage AJCC version 7: pathological tumor stage (pT-stage; pT1,
pT2, pT3, pT4) and pathological nodal stage (pN-stage: pN0, pN1, pN2);
2. Clinicopathological features: age (continuous), sex, primary site location
(right [caecum to transverse colon] versus left [splenic ﬂexure to sig-
moid]), number of positive LNs (continuous), number of examined LNs
(continuous), tumor grade (low or medium versus high), type of adju-
vant chemotherapy type (oral/infusional/bolus 5FU variations versus
5FU and oxaliplatin, 5FU and oxaliplatin plus cetuximab, 5FU and irino-
tecan, 5FU and irinotecan plus cetuximab).
3. Molecular markers: MSI status (MSI-high versus microsatellite stable
[MSS] or MSI-low), mutations in BRAFV600E or KRAS codons 12/13.
Datasets splits, summarized in Figure 1 and Table 1, were as follows:
1. Training (train) and internal validation (val1): Clinical trial cohorts
a. N0147 (NCT00079274) (n¼3392) [13]: Treated with adjuvant infu-
sional 5FU and oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) with
or without cetuximab in stage III CC patients;
b. PETACC-3 (NCT00026273) (n¼1404) [15]: Treated with adjuvant
infusional 5FU with or without irinotecan (FOLFIRI) in high-risk
stage II or stage III CC patients.
2. External validation cohorts (val2-val4): Observational studies
a. CCFR (Colon Cancer Family Registry; n¼2058) [16]: Four datasets
of stage II or III CC patients (treated, untreated, unknown adjuvant
therapy status);
b. CRCSC (Colorectal Cancer Subtyping Consortium; n¼609) [17]:
Four datasets of stage II or III CC patients (treated, untreated, un-
known adjuvant therapy status);
c. OSLO (Oslo University Hospital; n¼609) [18]: Consecutive,
population-based series of stage II or III CC (treated or untreated).
All patients with stage II tumors from clinical trial cohorts (PETACC-
3 only) were allocated to the train data, and those with stage III tumors
were randomly distributed in train (2/3 of samples) and val1 (1/3 of sam-
ples). Data split in the external validation cohorts was based on
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availability of complete clinicopathological annotation and adjuvant
therapy: val2 (chemotherapy-treated with complete annotation); val3
(untreated with complete annotation); val4 (unknown adjuvant therapy
status or missing clinicopathological annotation).
Methods—statistical considerations
In total, 2821 samples had missing values for one or more covariates.
Patterns of co-missingness among multiple covariates were generally at-
tributable to the specific data collection patterns of individual studies.
As a result, missing data was not missing at random (MAR), resulting in
a subset of samples (n¼ 1910) with missing parameters that could not
be imputed. For the remaining samples (n¼ 991), multiple imputation
was carried out via the “mice” R package [19], separately for each co-
hort, with all variables except adjuvant therapy. Samples from valid-
ation cohorts that could not be imputed were aggregated in val4. A
subset of these samples (n¼ 782) had annotation on TNM staging plus
molecular markers and was used to validate models that did not include
clinicopathological features or had unknown adjuvant treatment
information.
Following imputation, multivariable Cox proportional hazards mod-
els were formulated using factors that demonstrated statistical signifi-
cance for OS in univariate models (with P< 0.10 according to a log-rank
test). Age was modeled using restricted cubic splines. The proportional
hazards assumption was verified (P¼0.22 across different cohorts;
P>0.05 across different datasets within each cohort) and all Cox models
were stratified by dataset.
We constructed models with TNM staging alone (TNM), TNM plus
molecular markers (TNM.Mol), TNM plus clinicopathological features
(TNM.Clin.Path) and all covariates (TNM.Clin.Path.Mol). Final models
were validated both internally (train and val1) and externally (val2–val4)
to obtain optimism-corrected discrimination for survival data via c-indi-
ces, tAUCs and iAUC (1–5 years) using “timeROC” R package [20].
Stage-proportional 5-fold data splitting was performed for internal
validation in the train set. We selected a Bayesian method for model com-
parison—in validation cohorts with complete annotation on markers of
interest (val1–val3), the corresponding iAUCs were cross-compared
using Bayes factor estimation [21] and bootstrapping procedure. We cal-
culated the relative proportion of explained variance (Cox & Snell pseudo
R2) in OS that is accounted for by different categories of predictor covari-
ates using “survival” R package. Calibration plots of predicted probability
versus observed proportion were generated using the “rms” R package.
All analyses were performed using R statistical software version 3.2.5
[22].
Results
Association among molecular markers and
clinocopathological features
We explored the association of molecular markers and TNM
stage and primary site location in the complete patient cohort of
stage I, II and III CC (supplementary Figure S1, available at
Annals of Oncology online). There was a stepwise decrease in
prevalence of KRAS or BRAF V600E mutations (mutually exclusive
in our cohort) moving from the right to left colon (supplemen
tary Figure S1A, available at Annals of Oncology online). KRAS or
BRAF V600E mutations were 2 times more likely to be found in
the caecum as compared to sigmoid colon (supplementary Figure
S1A, available at Annals of Oncology online). The prevalence of
BRAFV600E mutations and MSI-high status paralleled each other
and exhibited a bell-shaped distribution, with an increase from
the caecum to hepatic flexure, then gradual decrease through sig-
moid colon (supplementary Figure S1A, available at Annals of
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Oncology online). MSI-high status was 4 times more prevalent
in tumors of the right colon as compared to the left, and 2 times
higher in stage II versus stage III tumors (supplementary Figure
S1B, available at Annals of Oncology online). KRAS and
BRAFV600E mutations were equally distributed across stages (sup
plementary Figure S1C and D, available at Annals of Oncology on-
line). KRAS mutations were 2 times more frequent in MSS/MSI-
low compared to MSI-high tumors (supplementary Figure S1C,
available at Annals of Oncology online). On the contrary,
BRAFV600E mutations were 8 times more prevalent in MSI-high
Table 1. Demographics and disease characteristics of patients included in overall survival models postimputation
Train Val1 Val2 Val3 Val4 P value
Dataset
N0147 2318 943 0 0 0
PETACC-3 698 556 0 0 0
CRCSC 0 0 368 189 52
CCFR 0 0 473 401 730
Oslo 0 0 108 490 0
Total 3016 1499 949 1080 782
TNM staging <0.001
IIA 318 (10%) 0 336 (35%) 756 (70%) 320 (40%)
IIB/IIC 77 (3%) 0 61 (7%) 78 (7%) 22 (3%)
IIIA 292 (10%) 170 (11%) 50 (5%) 11 (1%) 59 (8%)
IIIB 1795 (59%) 1034 (69%) 359 (38%) 147 (14%) 342 (44%)
IIIC 534 (18%) 295 (20%) 143 (15%) 88 (8%) 39 (5%)
Clinicopathological
Age in years <0.001
Median (range) 59 (19–85) 59 (21–86) 62 (22–96) 70 (24–94) NA
Sex 0.004
Female 1374 (46%) 694 (46%) 465 (46%) 551 (51%) NA
Male 1642 (54%) 805 (54%) 484 (54%) 529 (49%) NA
Lymph nodes assessed <0.001
Median (IQR) 17 (12–23) 16 (11–22) 11 (6–19) 10 (6–21) NA
Tumor grade <0.001
Low/medium 2382 (79%) 1212 (81%) 811 (84%) 981 (91%) NA
High 634 (21%) 287 (19%) 148 (16%) 99 (9%) NA
Primary tumor site <0.001
Right colon 1464 (49%) 688 (46%) 482 (51%) 647 (60%) NA
Left colon 1552 (51%) 811 (54%) 467 (49%) 433 (40%) NA
Adjuvant chemotherapy <0.001
None 0 0 0 1080 (100%) NA
5FU/capecitabine 359 (12%) 274 (18%) 852 (90%) 0 NA
FOLFIRIa 415 (14%) 313 (21%) 4 (1%) 0 NA
FOLFIRIa/cetuximab 32 (1%) 9 (1%) 0 0 NA
FOLFOXb 1228 (41%) 550 (37%) 93 (9%) 0 NA
FOLFOXb/cetuximab 982 (32%) 353 (23%) 0 0 NA
Molecular <0.001
MSI status
MSI-high 383 (13%) 183 (12%) 182 (19%) 276 (26%) 135 (17%)
MSS/MSI-low 2633 (87%) 1316 (88%) 767 (81%) 804 (74%) 647 (83%)
BRAF V600E status <0.001
Mutated 345 (11%) 162 (11%) 124 (13%) 205 (19%) 102 (13%)
Wild-type 2671 (89%) 1337 (89%) 825 (87%) 875 (81%) 680 (87%)
KRAS codons 12/13 status <0.001
Mutated 1078 (36%) 566 (38%) 349 (37%) 331 (31%) 239 (31%)
Wild-type 1938 (64%) 933 (62%) 600 (63%) 749 (69%) 543 (69%)
aInfusional 5FU with irinotecan.
bInfusional 5FU with oxaliplatin.
NA, not applicable.
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as compared to MSS/MSI-low tumors (supplementary Figure
S1D, available at Annals of Oncology online). Finally, we observed
a higher proportion of high-grade tumors with increasing pT
(pT1–pT4) and pN (pN0–pN2) stage, with 2 times higher
prevalence of poorly differentiated carcinomas in MSI-high
tumors as compared to MSS/MSI-low (supplementary Figure
S1E, available at Annals of Oncology online).
Prognostic associations
Demographics, tumor-related characteristics and molecular
markers of the different cohorts of patients with stage II or III CC
included in survival models are described in Table 1. As a result
of our data split approach, the training and external validation
cohorts are heterogeneous with respect to adjuvant chemother-
apy treatment and additional covariates. In univariate Cox mod-
els, all clinicopathological features and molecular markers
demonstrated a statistically significant association with OS in
both the training and all validation cohorts (data not presented).
Figure 2 illustrates Kaplan–Meier OS curves in clinical trial co-
horts and observational studies, with stratification by molecular
subgroup. Overall, hazard ratios for the association of BRAFV600E
or KRAS mutations with worse OS were repeatedly significant in
MSS/MSI-low tumors (supplementary Table S1, available at
Annals of Oncology online). Patients whose tumors were MSS/
MSI-low and BRAFV600E mutated had the highest risk of death
across all cohorts. Five-year OS rates in stage III CC patients
treated with oxaliplatin-based adjuvant chemotherapy (train)
ranged from 62% (95% CI 56–70%) if the tumors were MSS/
MSI-low BRAFV600E mutated to 83% (95% CI 77–90%) if the
tumors were MSI-high KRAS/BRAFV600E wild-type. The corres-
ponding numbers in stage II untreated CC patients (val3) were
66% (95% CI 52–85%) and 90% (95% CI 80–99%), respectively.
In multivariable analyses, detailed in Table 2, all examined fac-
tors were statistically significant for OS prediction in the train
and val1 cohorts (clinical trial data). In val2 and val3 cohorts
(complete clinicopathological annotation), MSI status and
BRAFV600E mutations remained independent prognostic factors,
together with pT and pN staging. We found no statistically sig-
nificant interaction between molecular markers and clinicopa-
thological features with impact on patient outcomes. The TNM
model for OS demonstrated a c-index of 0.66 and iAUC of 0.68 in
the training set, while the full TNM.Clin.Path.Mol model had c-
index of 0.73 and iAUC of 0.76. The calibration of observed ver-
sus predicted 5-year OS rates in the training cohort was strong
across the spectrum of ordered risk groups (supplementary
Figure S2, available at Annals of Oncology online). Model’s c-indi-
ces in the training and validation cohorts are shown in Figure 3A.
Across different validation cohorts, c-indices increased from
0.61–0.68 in the TNM alone model to 0.63–0.71 in models with
added molecular markers, 0.65–0.73 with clinicopathological fea-
tures and 0.66–0.74 with all covariates (supplementary Table S2,
available at Annals of Oncology online). The iAUC increased from
0.644 for the TNM system model to 0.667 for the TNM.Mol
model, 0.671 for the TNM.Clin.Path model and 0.675 for the
TNM.Clin.Path.Mol model. Inspection of K-values from Bayes
factor estimation in different validation cohorts with complete
annotation (supplementary Table S3, available at Annals of
Oncology online) and corresponding bootstrapped iAUCs
(Figure 3B and supplementary Table S4, available at Annals of
Oncology online) confirmed that there is strong evidence that all
models with clinicopathological features and/or molecular
markers provide significantly improved OS prediction when
compared to TNM-only models. On the other hand, when com-
paring the TNM.Clin.Path.Mol model with gold standard
TNM.Clin.Path model in patient cohorts patients treated with
adjuvant chemotherapy (val1 and val2), we did not find evidence
for superiority, with K-values less than 2 (supplementary Table
S4, available at Annals of Oncology online). Detailed tAUCs of
models are shown in supplementary Figure S3, available at
Annals of Oncology online.
Risk discrimination was consistently better in patient cohorts
that received adjuvant chemotherapy, mirroring the training
data. We then focused on this population (train, val1 and val2) to
illustrate the relative contribution of different factors for progno-
sis prediction (Figure 3C). In multivariable models, the relative
proportion of variance explained (R2) by TNM staging, clinico-
pathological features and molecular markers was 59%, 31% and
10%, respectively, in clinical trial cohorts. The corresponding
numbers in observational studies were 72%, 18% and 10%.
Discussion
In an era of precision medicine and increased public awareness
and access to health information, movement toward individual-
ized prognostic estimation is critical for both treatment planning
and patient–physician communication. In this study we
focused on well-defined cancer cell molecular markers in
intermediate-risk CC. First, we confirmed that the prevalence of
KRAS and BRAFV600E mutations and MSI-high varies signifi-
cantly throughout the colon [13]. Other studies have shown that
the biological differences between right- and left-sided carcin-
omas also extend to the gene expression level, which translate
into different prognosis and response to anti-EGFR therapy [23,
24]. Indeed, we found that primary tumor site was one of the
strongest clinicopathological determinants of survival, with
worse outcomes for those diagnosed with right-sided tumors.
Next, we investigated to what extent these markers impact the
prediction of 5-year OS in multivariable models that include pa-
tient and disease characteristics. The selection of OS as the end-
point of interest is based on its proven association with the
AJCC-TNM staging system, unambiguous clinical relevance and
unbiased interpretation. We demonstrated that there is a statis-
tically significant increase in the performance of models when
KRAS/BRAF mutation and MSI status are added to TNM models.
Therefore, from an individual patient perspective, these molecu-
lar markers significantly improve the ability to discriminate risk
of death over TNM staging alone. Interestingly, the molecular
markers tested in our series have high prognostic impact in small
subgroups of patients, particularly those whose tumors are MSS/
MSI-low and BRAFV600E mutated. On the contrary, from a popu-
lation or modeling perspective, there is marginal (albeit not stat-
istically significant) impact of adding this set of molecular
markers to clinicopathological models currently available to
make critical prognostic estimations. The existing data do not
support routine KRAS/BRAF mutation plus MSI testing, with its
added cost, for improved prognostic stratification of
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Figure 2. Overall survival Kaplan–Meier estimates across clinical trial cohorts of chemotherapy-treated patients (A and B), and multiple validation cohorts of chemotherapy-treated (C),
-untreated (D) or unknown adjuvant therapy status (E). Univariate Cox models are detailed in supplementary Table S1, available at Annals of Oncology online.
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nonmetastatic CC patients eligible to adjuvant chemotherapy as
per TNM staging and clinicopathological features. Therefore, our
results do not justify a revision of existing web-calculators for
widespread adoption by the medical community [4]. However, it
is important to emphasize that full models described here
achieved c-indices ranging from 0.70 to 0.74 in validation cohorts
treated with adjuvant chemotherapy (Figure 3A), numbers ex-
ceeding those that have been reported with models lacking mo-
lecular annotation (c-index of 0.66) [4, 5]. This may be in part
related to more accurate TNM staging and clinicopathological
annotation in the contemporary cohorts included in our study.
Major strengths of our work include compliance with AJCC
recommendations for potential model endorsement [7], and the
significant clinicopathological and molecular heterogeneity in
the validation datasets, reflecting major differences in clinical
trial cohorts and observational studies—which increases general-
izability of our findings. We recognize that clinicopathological
annotation available for modeling in our series is not complete,
and some covariates with well-established prognostic impact
were not examined, including lymphovascular and perineural in-
vasion, and tumor presentation with obstruction or perforation
[9]. Another limitation of our study is the lack of annotation on
exposure to these targeted agents in the metastatic setting, which
is known to interact with KRAS/BRAF mutations. Nevertheless,
the differences in OS according to molecular subgroups depicted
in Figure 2 are likely related not only to patient outcome in the
Table 2. Final multivariable overall survival Cox models across clinical trial cohorts and different observational studies
Cohorts with adjuvant
chemotherapy exposure
Train (n53016; 550 events) Val1 (n51499; 307 events) Val2 (n¼949; 151 events)
HR 95% CI P value HR 95% CI P value HR 95% CI P value
pT3 versus pT2/pT1 2.43 1.59 3.73 <0.001 1.67 1.05 2.66 <0.001 1.45 0.66 3.17 0.35
pT4 versus pT2/pT1 4.83 3.08 7.59 <0.001 2.81 1.69 4.66 <0.001 3.39 1.47 7.84 0.004
pN1 versus pN0 1.79 1.20 2.66 0.004 NA NA NA NA 2.69 1.66 4.37 <0.001
pN2 versus pN0a 3.09 2.04 4.68 <0.001 1.47 1.09 1.98 0.01 3.27 1.86 5.72 <0.001
Age in years (continuous) 1.01 1.00 1.02 0.01 1.01 1.00 1.02 0.02 1.01 1.00 1.03 0.07
Male versus female 1.36 1.15 1.62 <0.001 1.48 1.17 1.88 0.001 1.28 0.92 1.78 0.14
LN assessed 12 versus <12 0.74 0.60 0.91 0.004 0.63 0.48 0.83 <0.001 1.17 0.84 1.62 0.35
LN positive (continuous) 1.06 1.04 1.08 <0.001 1.11 1.07 1.14 <0.001 1.08 1.04 1.12 <0.001
High grade versus low/medium 1.35 1.11 1.64 0.003 1.35 1.11 1.64 0.003 1.38 0.93 2.05 0.11
Right colon versus left colon 1.46 1.21 1.77 <0.001 1.65 1.28 2.12 <0.001 1.31 0.92 1.85 0.13
FOLFIRIb versus 5FU/LV 1.15 0.81 1.62 0.44 0.86 0.61 1.20 0.37 NA NA NA NA
FOLFIRIb/cetuximab versus 5FU/LV 0.54 0.19 1.50 0.24 0.36 0.05 2.62 0.31 NA NA NA NA
FOLFOXc versus 5FU/LV 0.76 0.55 1.05 0.09 0.65 0.47 0.90 0.01 0.77 0.47 1.26 0.3
FOLFOXc/cetuximab versus 5FU/LV 0.97 0.70 1.35 0.88 0.83 0.59 1.17 0.29 NA NA NA NA
MSI-high versus MSS/MSI-low 0.75 0.57 0.99 0.043 0.72 0.49 1.05 0.08 0.44 0.25 0.77 0.004
BRAF V600E mutation versus wt 1.63 1.25 2.12 <0.001 2.53 1.78 3.60 <0.001 1.94 1.19 3.16 0.007
KRAS codons 12/13 mutation versus Wt 1.49 1.24 1.81 <0.001 1.42 1.10 1.84 0.007 1.35 0.95 1.93 0.09
Cohorts without adjuvant
chemotherapy exposure
Val3 (n51080; 286 events) Val4 (n5782; 179 events)
HR 95% CI P value HR 95% CI P value
pT3 versus pT2/pT1 1.77 0.65 4.83 0.26 4.46 1.64 12.15 0.004
pT4 versus pT2/pT1 3.29 1.16 9.35 0.02 11.18 3.64 34.39 <0.001
pN1 versus pN0 1.45 1.04 2.01 0.03 1.82 1.31 2.53 <0.001
pN2 versus pN0 1.72 1.11 2.64 0.01 1.53 0.86 2.74 0.14
Age in years (continuous) 1.05 1.04 1.07 <0.001 NA NA NA NA
Male versus female 1.08 0.85 1.38 0.52 NA NA NA NA
LN assessed 12 versus <12 1.22 0.97 1.55 0.09 NA NA NA NA
LN positive (continuous) 1.04 1.00 1.07 0.03 NA NA NA NA
High grade versus low/medium 0.99 0.63 1.55 0.97 NA NA NA NA
Right colon versus left colon 0.70 0.54 0.91 0.007 NA NA NA NA
MSI-high versus MSS/MSI-low 0.49 0.32 0.77 0.002 0.97 0.64 1.47 0.88
BRAF V600E mutation versus wt 1.64 1.03 2.62 0.04 1.72 1.10 2.69 0.02
KRAS codons 12/13 mutation versus wt 1.13 0.87 1.48 0.36 1.28 0.92 1.78 0.13
aIn Val2, pN2 versus pN1.
bInfusional 5FU with irinotecan.
cInfusional 5FU with oxaliplatin.
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metastatic setting but also to the risk of disease relapse. Indeed,
previous reports from clinical trials included in our study have
shown that both disease-free survival and survival after relapse are
affected by MSI status and KRAS/BRAFV600E mutations [12, 13].
Lastly, in an era of next-generation sequencing in clinical labs,
other patient subgroups with specific molecular changes that
have strong impact for precision medicine may be identified,
such as the recently described subpopulation with POLE muta-
tions [25]. Additionally, nongenetic markers linked to micro-
environment components have demonstrated independent
prognostic value in stage I to III CC. These include immune infil-
tration patterns—tumor infiltrating lymphocytes [26] and
immunoscore [27], e.g.—and gene expression signatures that re-
flect stromal infiltration with epithelial–mesenchymal transition
[17] or activated cancer-associated fibroblasts [28, 29].
Interestingly, these signatures may correlate with an immuno-
suppressive microenvironment [30] and resistance to standard
adjuvant chemotherapy [31, 32], supporting the idea that an acti-
vated immune microenvironment in early stage CC is a strong
determinant of the risk of distant dissemination. Future studies
evaluating predictive performance of survival models in CC
should incorporate larger mutation panels and signatures that re-
flect immune and stromal activation status, and take into account
therapies received after relapse, particularly targeted agents and
immunotherapies that potentially interact with molecular
markers.
To conclude, we believe that our work represents a foundation
for similar efforts trying to optimize prognostic stratification of
CC by integrating molecular markers with clinicopathological
features. Such an individualized and comprehensive approach to
prognostication, with model-based staging, will aid in patient–
physician communication, development of rational follow-up
schedules and hopefully risk-adaptive therapies.
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